AU2023244526A1 - Thrombopoietin receptor fragments and uses thereof - Google Patents

Thrombopoietin receptor fragments and uses thereof Download PDF

Info

Publication number
AU2023244526A1
AU2023244526A1 AU2023244526A AU2023244526A AU2023244526A1 AU 2023244526 A1 AU2023244526 A1 AU 2023244526A1 AU 2023244526 A AU2023244526 A AU 2023244526A AU 2023244526 A AU2023244526 A AU 2023244526A AU 2023244526 A1 AU2023244526 A1 AU 2023244526A1
Authority
AU
Australia
Prior art keywords
polypeptide
calr
amino acid
tpor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023244526A
Other languages
English (en)
Inventor
Stefan CONSTANTINESCU
Audrey NEDELEC
Nicolas PAPADOPOULOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of AU2023244526A1 publication Critical patent/AU2023244526A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2023244526A 2022-04-01 2023-03-31 Thrombopoietin receptor fragments and uses thereof Pending AU2023244526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166302.4 2022-04-01
EP22166302 2022-04-01
PCT/EP2023/058572 WO2023187201A1 (en) 2022-04-01 2023-03-31 Thrombopoietin receptor fragments and uses thereof

Publications (1)

Publication Number Publication Date
AU2023244526A1 true AU2023244526A1 (en) 2024-10-17

Family

ID=81580134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023244526A Pending AU2023244526A1 (en) 2022-04-01 2023-03-31 Thrombopoietin receptor fragments and uses thereof

Country Status (6)

Country Link
US (1) US20250250320A1 (https=)
EP (1) EP4504770A1 (https=)
JP (1) JP2025511108A (https=)
AU (1) AU2023244526A1 (https=)
CA (1) CA3246911A1 (https=)
WO (1) WO2023187201A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230368A2 (en) * 1999-11-18 2002-08-14 Schering Corporation Mammalian receptor proteins; related reagents and methods

Also Published As

Publication number Publication date
JP2025511108A (ja) 2025-04-15
WO2023187201A1 (en) 2023-10-05
CA3246911A1 (en) 2023-10-05
EP4504770A1 (en) 2025-02-12
US20250250320A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
JP7082051B2 (ja) 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法
EP3013854B1 (en) Cd86 variants with improved affinity for ctla-4
JP2022023184A (ja) アクチビン－ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
ES2972783T3 (es) Tratamiento de las neoplasias malignas hematológicas
AU2014346537A1 (en) Methods of using interleukin-10 for treating diseases and disorders
JP2020191860A (ja) Ｉｌ−３７バリアント
US20250051410A1 (en) Lilrb polypeptides and uses thereof
WO2013177593A2 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
JP2023521867A (ja) 改変インターロイキン２２ポリペプチド及びその使用
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
CN111315880A (zh) 突变型aim
US20250241986A1 (en) Soluble thrombopoietin receptor fragments and uses thereof
US20250304651A1 (en) Treatment of haematological malignancies
US20190024070A1 (en) Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
NL2019156B1 (en) Treatment of haematological malignancies
WO2024044647A1 (en) Flt3 ligand bi-functional molecules for thrombopenia and acute radiation syndrome
CN118786137A (zh) Lilrb多肽及其用途
EP3927736A1 (en) A membrane-bound fit-1 decoy and uses thereof